UK-EU research partnerships benefit patients across Europe
A report commissioned by eight leading UK medical organisations highlights how partnerships between UK and EU medical researchers have increased the value of research, benefiting patients across Europe.
This new research shows how the UK’s contribution to research throughout the EU has fostered and strengthened scientific cooperation in the following areas.
Clinical trials have benefited from UK and EU researchers working together, especially for rarer diseases where the UK has the highest number of trials.
As the number of patients with rarer conditions in each country is low, it’s only possible to recruit enough patients for clinical trials by carrying out trials across countries.
The leadership role played by UK researchers in Europe is reflected through their extensive membership of scientific committees and panels.
UK researchers account for 17% of the scientific advisory boards membership at Germany’s Max Planck Institutes, the highest proportion from one country.
And between 2008 and 2016, the UK’s Medicines and Healthcare Products Regulatory Agency acted as scientific advice coordinator in at least a fifth of centralised European Medicines Agency approvals.
Treatments and devices
Experts from across Europe were interviewed for this report. Many highlighted the UK’s ability to conduct translational research to discover treatments and devices that can benefit patients across Europe.
This has included:
developing a new generation of genetically targeted personalised medicines
interventions for wellbeing and mental health.
The report also highlights the UK’s role as a trainer of scientists:
about 16,000 students from EU countries are enrolled on biomedical courses at UK higher education institutes
about 20% of EU nationals trained in the UK take up positions in other European countries.